Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125

Gynecologic Oncology

Volumn 94, Issue 3, 2004, Pages 811-813

  Allen, Gregory W ^b   Forouzannia, Afshin ^b   Bailey, Howard H ^b   Howard, Steven P ^a  

^a University of Wisconsin Health   (United States)

^b NONE

Author keywords

CA 125; Pelvic Non Hodgkin's Lymphoma

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ERROR; DYSPNEA; FATIGUE; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PARACENTESIS; PELVIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SATIETY; THORACOCENTESIS; TUMOR BIOPSY; WEIGHT REDUCTION;

CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 4444292499     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.057     Document Type: Article

References (10)

1. Bast R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., Berkowitz R.S., Leavitt T., Griffiths C.T., Parker L., Zurawski V.R., Knapp R.C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309(15):1983;883-887
2. NIH consensus development panel on ovarian cancer: NIH consensus conference. Ovarian cancer. Screening, treatment and follow-up. JAMA. 273(6):1995;491-497
3. Hogdall C.K., Mogensen O., Tabor A., Mogensen B., Jakobsen A.K., Norgaard-Pedersen B., Larsen S.O., Clemmensen I. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol. Oncol. 56(1):1995;22-28
4. Ravoet C., Dargent J.L., Le Moine F., Feremans W. CA-125 in primary mediastinal B-cell lymphoma with sclerosis. J. Clin. Oncol. 13(2):1995;530-535
5. Kutluk T., Erbas B., Buyukpamukcu M. Serum CA 125 levels in children with non-Hodgkin's lymphoma. Pediatr. Hematol. Oncol. 16(4):1999;311-319
6. Zeillemaker A.M., Verbrugh H.A., Hoynck van Papendrecht A.A., Leguit P. CA 125 secretion by peritoneal mesothelial cells. J. Clin. Pathol. 47(3):1994;263-265
7. Pabst T., Ludwig C. CA-125: A tumor marker in non-Hodgkin's lymphomas? J. Clin. Oncol. 13(7):1995;1827-1828
8. Fehm T., Beck E.E., Valerius T., Gramatzki M., Jager W. CA 125 elevations in patients with malignant lymphomas. Tumour. Biol. 19(4):1998;283-289
9. Lazzarino M., Orlandi E., Klersy C., Astori C., Brusamolino E., Corso A., Bellio L., Gargantini L., Morra E., Bernasconi C. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer. 82(3):1998;576-582
10. Zacharos D.I., Efstathiou S.P., Petreli E., Georgiou G., Tsioulos D.I., Mastorantonakis S.E., Christakopoulou I., Roussou PP. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma. Eur. J. Haematol. 69(4):2002;221-226